Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?. Issue 1 (1st July 2021)

• Record Type: Journal Article
• Authors: Alagna, Riccardo; Cabibbe, Andrea Maurizio; Miotto, Paolo; Saluzzo, Francesca; Köser, Claudio Umberto; Niemann, Stefan; Gagneux, Sebastien; Rodrigues, Camilla; Rancoita, Paola Vittoria Maria; Cirillo, Daniela Maria
• Is Part Of: European respiratory journal. Volume 58:Issue 1(2021)
• Publication Date: 2021-07-01
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00959-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

The World Health Organization (WHO) recently endorsed a new definition of extensively drug-resistant tuberculosis (XDR-TB) and, for the first time, introduced the category of pre-XDR-TB [1]. Pre-XDR-TB is defined as multidrug resistance/rifampicin resistance (MDR/RR) in conjunction with resistance to any fluoroquinolone (levofloxacin or moxifloxacin), whereas the conditions for XDR-TB are now met by additional resistance to a group A drug (bedaquiline or linezolid) [1]. The new definition of extensively drug resistant tuberculosis endorsed by WHO poses some challenges that must be addressed in a coordinated fashion by researchers, TB control stakeholders and assay developers https://bit.ly/3eAMU8B